Last reviewed · How we verify
NCT05402449
To Evaluate the Beneficial Effect of Probiotics on NAFLD Patients and the Role of Gut Microbiota Modulation
NA trial testing Placebo in Non-Alcoholic Fatty Liver Disease in 70 participants. Completed in 31 May 2024.
31 May 2024
Quick facts
| Lead sponsor | GenMont Biotech Incorporation |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | supportive care |
| Enrollment | 70 |
| Start date | 14 July 2022 |
| Primary completion | 31 May 2024 |
| Estimated completion | 31 May 2024 |
| Sites | 1 location across Taiwan |
Drugs / interventions tested
- Placebo
- Probiotics — full drug profile →
Conditions studied
- Non-Alcoholic Fatty Liver Disease — all drugs for Non-Alcoholic Fatty Liver Disease →
Sponsor
GenMont Biotech Incorporation — full company profile →
Who can join
Adults 20 to 80, any sex, with Non-Alcoholic Fatty Liver Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this study, the improvement of the clinical status of early-stage non-alcoholic fatty liver disease (NAFLD) patients after the probiotic intervention will be assessed. And the mechanism of probiotics to prevent the progression of illness would be investigated. The chronic inflammation status, systemic oxidative stress, metabolism of carbohydrates and lipid, and gut microbiota of NAFLD patients will also be analyzed.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
Gut liver brain axis in diseases: the implications for therapeutic interventions.
Yan M, Man S, Sun B, Ma L, et al · · 2023 · cited 165× · PMID 38057297 · DOI 10.1038/s41392-023-01673-4 -
Non-alcoholic fatty liver disease: Immunological mechanisms and current treatments.
Petagine L, Zariwala MG, Patel VB. · · 2023 · cited 27× · PMID 37701135 · DOI 10.3748/wjg.v29.i32.4831 -
Targeting the Adipose Tissue-Liver-Gut Microbiota Crosstalk to Cure MASLD.
Gabbia D, De Martin S. · · 2023 · cited 10× · PMID 38132297 · DOI 10.3390/biology12121471 -
Roles of short-chain fatty acids in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis.
Zhang CY, Liu S, Sui YX, Yang M. · · 2025 · PMID 41368119 · DOI 10.4254/wjh.v17.i11.113756 -
Molecular mechanisms and clinical applications of gut microbiota-derived bioactive compounds in metabolic dysfunction-associated fatty liver disease.
Ma C, Wang J, Song X, Wang X, et al · · 2025 · PMID 41190061 · DOI 10.3389/fimmu.2025.1682755
Verify or expand the search:
- PubMed search for NCT05402449
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Probiotics
Trials testing the same drug.
- NCT07470645 — Effects of Probiotic Supplementation on Stress and Anxiety in Students · NA · not yet recruiting
- NCT06943235 — Study of Probiotics Combined With Concurrent Hyperfractionated ChemoRadiotherapy and Adebrelimab Immunomaintenance in th · Phase 2 · recruiting
- NCT06827964 — Practice of Nutrition Package in Myanmar · NA · not yet recruiting
- NCT06873165 — Development of Microbial Therapeutics for Metabolic-associated Fatty Liver Disease: From Mechanistic Investigations to C · NA · recruiting
- NCT06583720 — Comparative Study Between Photodynamic Therapy with LED Associated with Probiotics in the Treatment of Halitosis · Phase 1 · recruiting
Other recruiting trials for Non-Alcoholic Fatty Liver Disease
Currently open trials in the same condition.
- NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
- NCT07294963 — Impact of Lifestyle Interventions on Cognitive Decline in Non-alcoholic Fatty Liver Disease · NA · recruiting
- NCT07130318 — Mediterranean Diet in Familial Mediterranean Fever: Is Fatty Liver Affected by Addition of Aerobic Exercise · NA · recruiting
- NCT06355310 — Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease · Phase 2 · recruiting
- NCT06863376 — Evaluating the Safety and Efficacy of Carbocisteine in the Treatment of Nonalcoholic Fatty Liver Disease Patients · Phase 2 · recruiting
Other GenMont Biotech Incorporation trials
Trials by the same sponsor.
- NCT06039644 — To Evaluate the Clinical Efficacy of Probiotics in Patients With the Breast Cancer · NA · recruiting
- NCT05674981 — To Evaluate the Beneficial Effect of Probiotics on DKD Patients and the Role of Gut Microbiota Modulation · NA · completed
- NCT04566549 — The Safety and Efficacy Evaluation of Hair Products Containing Probiotics · Phase 2 · completed
- NCT04190485 — To Evaluate the Efficacy of Probiotics Toothpastes in Improvement of Gingivitis and Prevention of Periodontal Diseases V · NA · completed
- NCT04094129 — Evaluation of the Effect of Wismemo on Alzheimer's Dementia Patients · NA · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05402449 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by GenMont Biotech Incorporation
- Last refreshed: 5 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05402449.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing